Local Regulatory Experts
Connect with regulatory affairs consultancies specializing in this region.
Qualtech Consulting Corporation
Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA
A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.
ARQon Pte. Ltd.
Singapore (HQ), Malaysia, Vietnam, Indonesia, Philippines, Thailand, Taiwan, Hong Kong, South Korea, Switzerland, USA, Australia, New Zealand, Rwanda, India, Sri Lanka
We are a premier regulatory consultancy firm specializing in medical devices, in-vitro diagnostics (IVD), and pharmaceuticals. Founded in 2014, the company offers a comprehensive suite of services ranging from product development strategy and clinical trials to product registration and post-market surveillance. With a team of experts possessing vast experience in regulatory authorities and industry, we bridge the gap between scientific innovation and regulatory compliance, ensuring patient safety while fostering medical advancement. The company also provides unique business matching services through its ATTOPOLIS platform and training through the International Medical Device School.
CMIC Holdings Co., Ltd.
Tokyo, Japan (HQ), Osaka, Japan, Beijing, China, Seoul, South Korea, Taipei, Taiwan, Singapore, New York, USA, London, UK, Frankfurt, Germany, Sydney, Australia
We operate globally, specializing in accelerating the development, manufacturing, and commercialization of drugs and medical devices. Their expertise spans Phase I to IV clinical trials, regulatory affairs, quality assurance, and manufacturing, with a strong focus on the Japanese and Asian markets. Key services include clinical operations (CRO), manufacturing (CDMO/CMO), site management (SMO), and comprehensive health analysis and solutions.
EPSI GLOBAL PTE. LTD.
Singapore (HQ), Kuala Lumpur, Malaysia, Jakarta, Indonesia, Bangkok, Thailand, Hanoi, Vietnam, Manila, Philippines, Shanghai, China
We provide end-to-end regulatory solutions covering all classes of medical devices and IVDs in major APAC markets, especially the ASEAN region (Singapore, Malaysia, Indonesia, Thailand, Vietnam, Philippines) and major Northeast Asian markets (China, Korea, Japan). Services include classification, registration, local authorized representation, quality management system (QMS) implementation/auditing (ISO 13485/local GMP), and post-market surveillance. Their local presence minimizes market entry risks and time-to-market.
October 16, 2025
Approximately 5 minutes
Medical Device Classification in Singapore: A Risk-Based GHTF Approach
Medical Device Classification in Singapore: A Risk-Based GHTF Approach
The classification of medical devices (MD) and In Vitro Diagnostic (IVD) devices in Singapore is overseen by the Health Sciences Authority (HSA). The system is based on the guidelines established by the Global Harmonization Task Force (GHTF), which ensures a risk-based approach to regulation.
General Medical Device (MD) Classification
Medical devices are categorized into four classes, ranging from the lowest to the highest risk:
- Class A (Lowest Risk): Generally non-sterile, non-measuring devices with minimal potential for harm.
- Class B (Low to Moderate Risk): Devices that pose a low to moderate risk to the patient and user.
- Class C (Moderate to High Risk): Devices that pose a moderate to high risk, often due to longer-term contact with the body or more serious consequences if failure occurs.
- Class D (Highest Risk): Devices that pose the highest risk, typically life-sustaining implants or devices with major public health implications.
Factors Determining Risk Classification
The HSA's classification system considers multiple factors to determine the risk level, including:
- Intended Use: The primary purpose of the device.
- Degree of Invasiveness: Whether the device penetrates the body.
- Duration of Contact: How long the device is intended to be in contact with the patient.
- Delivery Method: How the device is introduced or used.
- Effectiveness of Risk Management: The degree to which risks can be mitigated during design and manufacturing.
In Vitro Diagnostic (IVD) Classification
IVD products are also classified from Class A (lowest risk) to Class D (highest risk). The risk level for IVDs is determined by:
- Intended Use: The purpose of the diagnostic test (e.g., general screening vs. critical diagnosis).
- Importance of Information: The impact of the test result on the individual and public health.
- Expertise of User: Whether the test is intended for professional use or self-testing (home use).
Example: A simple pregnancy test may be Class B, while an HIV blood test is Class D due to the severe public health implications and critical nature of the diagnostic information.
Special Classification Cases
1. Software as a Medical Device (SaMD)
Stand-alone software is classified based on its functionality and relationship to other devices:
- Influencing Other Devices: If the software influences the use of another medical device, its classification is determined by the intended use of the combined products.
- Independent Software: If the software is independent, it is classified according to Singapore's general rules, often as an active device.
2. Aesthetic and Telehealth Devices
- Telehealth Devices: Risk can range from Class A to Class C, depending on the monitoring function. For example, an app that only displays physiological factors is Class A, one that measures a single parameter is Class B, and one that performs continuous measurement (e.g., irregular heart rate) is Class C.
- Aesthetic-Related Purpose: Only high-risk devices intended for the modification of appearance or anatomy are regulated. These include:
- Any implant for the modification or fixation of any body part.
- Injectable dermal or mucous membrane fillers.
- Instruments used for the removal or degradation of fat by invasive means.
Related Articles
Approximately 5 minutes
Medical Device Registration in Singapore: HSA's Multi-Route Reliance System
Singapore's HSA regulates medical device registration using a risk-based classification (Class A-D) and four reliance pathways: Immediate, Expedited, Abridged, and Full. Registration requires a local **Registrant** and is facilitated by approvals in **Reference Countries** to streamline the process and reduce review timelines from 310 days (Full) to immediate.
Approximately 5 minutes
IVD Device Registration in Singapore: HSA's Risk-Based Reliance Pathways
The HSA regulates IVD devices in Singapore based on GHTF risk classification (A-D). Registration leverages approvals from **Reference Countries** to determine the pathway (Immediate, Expedited, Abridged, or Full), thereby significantly reducing review times, which can range from **0 working days** (Immediate) to **310 working days** (Full for Class D). All applications must be submitted by a local **Registrant**.
Approximately 5 minutes
Medical Device Grouping for Registration in Singapore: HSA's Cost-Saving Pathways
Singapore's HSA permits medical device and IVD manufacturers to consolidate multiple products into a single registration application through various grouping mechanisms, such as **Family**, **System**, and **Group**. This approach reduces costs and processing time, provided the devices share criteria like intended purpose, risk class, and design. Specific rules exist for IVD analyzers, test kits, and dental devices.
Approximately 5 minutes
Singapore's GDPMDS: The Mandatory QMS for Medical Device Distribution
The **Good Distribution Practice for Medical Devices (GDPMDS)**, formalized under SS 620:2016, is a mandatory Quality Management System (QMS) standard in Singapore. It is enforced by the **HSA** and required for all companies involved in the **importation and wholesale** of medical devices and IVDs. GDPMDS certification is the foundational step for obtaining a Medical Device Dealer's License.
Approximately 5 minutes
Singapore Medical Device Labeling: HSA Compliance and AMDD Harmonization
Singapore's HSA mandates medical device and IVD labeling be in **English** and align with the **ASEAN Medical Devices Directive (AMDD)**, detailed in **GN-23**. The label must contain information for safe identification and use, including product owner details, batch/lot number, and sterilization status. IVDs have additional requirements covering intended purpose, performance characteristics, and specimen type.
Approximately 5 minutes
Singapore Medical Device License Maintenance: Annual Fees and Change Notifications
Maintaining a medical device registration in Singapore requires payment of an **Annual Retention Fee** and mandatory reporting of all changes via **Registration Modification (Change Notifications)** to the HSA. Changes are categorized as Administrative, Review, or Technical, with processing times ranging from **30 to 90 days** depending on the device class and the nature of the change. Major changes, such as a change in intended use, require a **new product registration**.
Approximately 5 minutes
Singapore Post-Market Surveillance: Mandatory Adverse Event Reporting to HSA
Singapore's HSA mandates post-market surveillance for all medical devices under the Health Products Act. The local **Registrant/Distributor** is primarily responsible for reporting Adverse Events (AEs) occurring in Singapore, which must be reported within **48 hours (public health threat)** to **30 days (potential serious injury upon recurrence)**, depending on the severity. Manufacturers are responsible for providing all necessary information, with the clock starting immediately upon notification of the event.
Approximately 5 minutes
Singapore's SaMD Regulation: Cybersecurity, AI, and Lifecycle Compliance
The HSA regulates all Software as a Medical Device (SaMD), including AI and mobile apps, under a lifecycle approach. Registration requires adhering to the IMDRF risk classification and demonstrating a strong **cybersecurity strategy** (Secure-by-Design, threat modeling). SaMD labeling must include precise **versioning**, and changes, particularly to algorithms or AI features, are subject to rigorous **Change Notification** review.